Today we enrolled our 100th patient into our LiverPal RCT assessing whether longitudinal inpatient palliative care can improve outcomes for hospitalized patients with liver disease and their families. What a Good Friday! #palliativehepatology #livertwitter #liversky

Harvard redid its whole homepage to push back against the administration’s demands. I mean, this is just a website but I think it’s kind of a great PR move: www.harvard.edu

How many hospitalized patients need care in the ICU? How many of them survive? What interventions do they receive there? These are some of the questions I had two years ago while trying to write the "background" section for my masters thesis. But I couldn't find the answers... they did not exist.

As hepatologists, there are few things more devastating and very preventable that we see than HBV reactivation. If you are about to start your patient on an immunosuppressant, please keep this figure in mind. #LiverSky #MedSky https://buff.ly/4gaKqf7

Devastating read. #medsky jamanetwork.com/journals/jam...

#liversky Guys. Rifaximin

Albumin is the closest thing to a "universal remedy" in cirrhosis We use it to treat different complications, with good evidence but also with debatable or negative evidence Excellent analysis by Jonel Trebicka & @ggarciatsao.bsky.social doi.org/10.1097/hep.0000000000000521 #LiverSky

Just created a document titled "R01 SA page". So it begins. Both nervous but also really excited to think big. Advice, thoughts, prayers, etc. welcome! #LiverSky

“A donor wanted to give $2 million to my lab, but only wanted to allow a maximum 10 percent to go to indirect cost recovery. And the school declined to receive the $2 million because they wanted at minimum, I believe it was 20 percent.” www.harvardmagazine.com/2025/01/harv...

It is rare that an editorial will make me give a standing ovation to the authors - this one recently published in JAMA Internal Medicine by Kieran Quinn and colleagues did: https://buff.ly/4ggq9FS @kencovinsky.bsky.social #palliativehepatology #liversky #hapc

How do we apply the new SLD definitions in research? To study outcomes and implement trials for different SLD subtypes, we first need to be able to accurately identify each clinical entity using medical records/registry data. www.cghjournal.org/article/S154... @amergastroassn.bsky.social

@j-palliativemed.bsky.social Daniel Shalev et al respond to Susan Block's Special Report: Realizing the Imperative: The Future of Mental Health and Palliative Care Integration www.liebertpub.com/doi/10.1089/...

Everything you want to know about the management of depression and anxiety in #cirrhosis From Zimbrean (@YalePsych) and Jakab (@YaleDigestive) journals.lww.com/hepcomm/full... #liversky

"What do you want?" This is probably one of the most insidiously deceptive questions in medical decision-making. 1/8 #HAPC #MedSky #MedEd

Wonderful 1st day of @amcollegegastro.bsky.social #DEI Scholar Adjoa Anyane-Yeboa MD MPH in Department of Medicine at Tufts Medical Center Grand Rounds tomorrow: Leveling the Playing Field: Colorectal Cancer Screening in Historically Marginalize Populations

The always-thoughtful Derek Angus, master of the large randomized trial, calls for “a qualitative assessment of [the clinical team’s] experience [to] provide insight on how the intervention worked and on features considered unhelpful” The future of RCTs includes qual jamanetwork.com/journals/jam...

+1. Incredibly proud of the hard work that went into this comprehensive review on sudden cardiac arrest in athletes. Understanding these events in athletes has implications that echo far beyond the field and touches the health of all young adults. Full Text Link: bit.ly/3B1TxjT

Great summary of evidence for safety of naltrexone in liver disease 👇

Great question to ask our patients during a clinical encounter: "If we could help you with only one thing today, what would you want it to be?" Recommend this wise essay www.nejm.org/doi/full/10....

Continually inspired by Dan Shalev's work @pallipsych.bsky.social and excited for ongoing collaborations at intersection of mental health, palliative care, and cirrhosis/transplant care. #pallipsych #palliativehepatology

Let me tell you a story – one of the more haunting I’ve seen in 20 years of journalism. It’s about greed, death and denial. It took two years to unravel one doctor’s myth, a hospital’s complicity in creating it, and a documented trail of suspicious deaths…🧵

This is going to save hospitals a lot of money ! www.pennmedicine.org/news/news-re...

Two stages of writing: 1) This shouldn't take too long 2) Oh no

Do conversations about prognosis (defined as "conversation with your hepatologist about the likely outcome of your liver disease over time") cause patients w/ cirrhosis to lose hope? Simple answer: No Work led by🌟@donlan_john in CGH @amergastroassn.bsky.social https://buff.ly/4i1R6OM #LiverSky

Do conversations about prognosis (defined as "conversation with your hepatologist about the likely outcome of your liver disease over time") cause patients w/ cirrhosis to lose hope? Simple answer: No Work led by🌟@donlan_john in CGH @amergastroassn.bsky.social https://buff.ly/4i1R6OM #LiverSky

Amazing, formative work by my friend, collaborator, research role model @nnekauferemd.bsky.social Beyond the impact she is having on the care of people living with cirrhosis, she inspires me to think more expansively about what serious illness and #hspc palliative care are—and can be—as we grow…🧵

Psychological distress is prevalent and interdependent among patients with decompensated cirrhosis and their caregivers, confirming cirrhosis as a SHARED EMOTIONAL CONTAGION within dyads - our new study published in @AmJGastro #palliativehepatology journals.lww.com/ajg/abstract...

Nice to see Kavish Patidar recognizing our work led by Paige McLean Diaz on RRT decision-making in transplant ineligible patients at #TLM24. Is it time to trial serious illness communication & TLT interventions in the ACLF space? #palliativehepatology #LiverSky #NephSky @juancarlosqvelez.bsky.social

In the United States, HCC deaths may have plateaued and soon be on the decline due to successful HCV elimination However, persistent increases in MASLD and ALD-related HCC threaten these trends AASLD #TLM24 #Liversky

Validation of the Hospital Anxiety and Depression Scale in #cirrhosis 🫡 @nnekauferemd.bsky.social journals.lww.com/hepcomm/full...

Incredibly important numbers to keep in mind as we’re caring for patients with cirrhosis to frame our discussions with patients and families and involvement of palliative care @nnekauferemd.bsky.social discusses important solutions to facilitate patient-centered care at AASLD #TLM24

Ashley Spann just gave an utter MASTERCLASS on the use of technology in transplant care #TLM24

We've officially made it yall. Utibe Essien is on bluesky - give him a follow! @uressien.bsky.social #medsky

Ponni Perumalswami gave such a beautiful talk on management of alcohol-related liver disease at #TLM24 post-graduate course.

Alcohol, a big problem For everyone t.ly/eejfl This is a paper in JAMA from Sethi and Ramon. Please, #liversky, when you see Bataller at #TLM24, tell him he is needed here

The most effective pharmacological and hemodynamic intervention for the treatment of hepatorenal syndrome #HRS is a substantial MAP raise, as illustrated in this case example

The air smells so much cleaner here 😊. #liversky

In clinical research, you will often receive feedback on study design, stats, and/or data analysis from an editor or reviewer that is simply wrong. Here is a list of common "statistical myths" and references you can use to push back. discourse.datamethods.org/t/reference-...